Zoetis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Zoetis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ZTS

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. 

CEO
Kristin C. Peck
CEOKristin C. Peck
Employees
13,800
Employees13,800
Headquarters
Parsippany, New Jersey
HeadquartersParsippany, New Jersey
Founded
1952
Founded1952
Employees
13,800
Employees13,800

ZTS Key Statistics

Market cap
52.28B
Market cap52.28B
Price-Earnings ratio
20.29
Price-Earnings ratio20.29
Dividend yield
1.66%
Dividend yield1.66%
Average volume
5.06M
Average volume5.06M
High today
$121.33
High today$121.33
Low today
$118.47
Low today$118.47
Open price
$120.75
Open price$120.75
Volume
4.26M
Volume4.26M
52 Week high
$181.85
52 Week high$181.85
52 Week low
$115.25
52 Week low$115.25

Stock Snapshot

The current Zoetis(ZTS) stock price is $118.65, with a market capitalization of 52.28B. The stock trades at a price-to-earnings (P/E) ratio of 20.29 and offers a dividend yield of 1.7%.

As of 2025-12-05, Zoetis(ZTS) stock has fluctuated between $118.47 and $121.33. The current price stands at $118.65, placing the stock +0.2% above today's low and -2.2% off the high.

Zoetis(ZTS) shares are trading with a volume of 4.26M, against a daily average of 5.06M.

In the last year, Zoetis(ZTS) shares hit a 52-week high of $181.85 and a 52-week low of $115.25.

In the last year, Zoetis(ZTS) shares hit a 52-week high of $181.85 and a 52-week low of $115.25.

ZTS News

TipRanks 8h
Zoetis announces Health Canada approval for Portela

Zoetis (ZTS) announced that Health Canada has approved Portela for the alleviation of pain associated with osteoarthritis in cats. Designed to provide three mon...

Nasdaq 3d
S&P 500 Movers: ZTS, APP

In early trading on Tuesday, shares of Applovin topped the list of the day's best performing components of the S&P 500 index, trading up 6.4%. Year to date, App...

S&P 500 Movers: ZTS, APP
Simply Wall St 4d
What Zoetis's European Approval for Lenivia Means for Shareholders

In November 2025, Zoetis announced the European Commission granted marketing authorization for Lenivia®, its new long-acting monoclonal antibody therapy to redu...

What Zoetis's European Approval for Lenivia Means for Shareholders

Analyst ratings

76%

of 21 ratings
Buy
76.2%
Hold
23.8%
Sell
0%

People also own

Based on the portfolios of people who own ZTS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.